On-The-Spot Diagnosis for Cancer Patients
A case study produced by the Engineering and Physical Sciences Research Council (EPSRC). Researchers from the EPSRC-funded Nanoscale Physics Research Laboratory (NPRL) at the University of Birmingham, have developed a nanoscale device which can diagnose prostate cancer with more accuracy than current tests.
Prostate cancer is the most common cancer for men in the UK: over 10,000 men die from it every year. The ‘i-Screen’ biochip, a new screening device based on nanotechnology, will help doctors to diagnose the cancer earlier and with one hundred times more accuracy.
Over 30,000 men are diagnosed with prostate cancer in the UK every year, equivalent to roughly one diagnosis every 15 minutes. Unfortunately many of these diagnoses come too late. The university spin-out company Inanovate’s ‘i-Screen’ biochip could help doctors diagnose the disease accurately and spot the cancer in its earliest stages.
EPSRC is a part of the Research Councils UK (RCUK) partnership of research councils.
HEALTH and SAFETY
Any use of a resource that includes a practical activity must include a risk assessment. Please note that collections may contain ARCHIVE resources, which were developed at a much earlier date. Since that time there have been significant changes in the rules and guidance affecting laboratory practical work. Further information is provided in our Health and Safety guidance.
More like this
Resource by: Engineering and Physical Sciences Research Council
The resource is part of Research Councils UK
- Research Councils UK
- Engineering and Physical Sciences Research Council
- Impact! World Case Studies
- On-The-Spot Diagnosis for Cancer Patients